Grants

Grants

Molecular characterization and behaviour of tumors arising in patients taking 5-alpha reductase inhibitors, Movember Discovery Grant Application, Approved June 2015

  • Robert J. Hamilton, MD MPH FRCSC, Staff Urologist, Princess Margaret Cancer Centre   

Co-Investigator:     Eshetu Atenafu, M.Sc., Pstat , Senior Biostatistician

 

Applying radiomics to predict pathology of residual retroperitoneal nodal masses in metastatic germ cell tumors following platinum based chemotherapy  (Approved Aug 2015-Dec 2016)

PI:       Jeremy Lewin, Philippe Bedard, Princess Margaret Cancer Centre

  • :            Eshetu Atenafu, M.Sc., Pstat , Senior Biostatistician

PI Forsyth, Peter, Wang, L. et al: Phase I pharmacodynamic and “high content” study of the gamma-secretase inhibitor RO4929097 in patients with recurrent malignant gliomas (MGs) targeting p75NTR to inhibit brain tumour initiating cells (BTICs) and recurrent invasive gliomas CCSRI (2010-2012)

2019-2022                 CIHR, Canadian Institutes of Health Research

Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer

$544,119 – PI –S Sridhar;Co-I – W Xu

 

2019-2023                   CIHR, Canadian Institutes of Health Research

Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer

$750,000 – PI – W Xu, G Yousef, N Fleishman;Co-I – L Klotz

 

2019-2023                   CIHR, Canadian Institutes of Health Research

Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract

$ 757,352 – PI – S Bratman;Co-I - W Xu

 

2018-2021                   Prostate Cancer Canada

Combination of subpathology and noncoding RNA: integrating outcome prediction and treatment individualization for intermediate-risk prostate cancer

$1,499,250 – PI – Housheng He;Co-I - W Xu

 

2018-2022                   CIHR, Canadian Institutes of Health Research

Early detection of cancer in high-risk patients through profiling of circulating tumour DNA

$1,977,525 – PI - T Pugh;Co-I - W Xu

 

2018-2021                   Princess Margaret Cancer Centre Foundation

                                    Artificial Intelligence, Data Science, and Microbiome Research

$1,000,000 – PI: W Xu, L Siu, B Haibe-Kains,B Coburn

 

2018-2020                   CCC, Crohn’s and Colitis Canada

                                    The Crohn’s and Colitis Canada GEM Project

$4,000,000 – PI: - K Croitoru;Co-I - W Xu

 

2017-2022                   CIHR, Canadian Institutes of Health Research

Seeking Molecular Signatures for Nasopharyngeal Carcinoma 

$1,147,500 – PI –F Liu; Co-I – W Xu

 

2017-2021                   OICR, Ontario Institute for Cancer Research

Ovarian Cancer Translational Research Initiative 

$10,000,000 – PI –A Oza, R Rottapel; Co-I – W Xu

 

2017-2022                   NSERC, Natural Sciences and Engineering Research Council of Canada

Methodology Development and Implementation for Microbiome Sequencing Data: Hierarchical Modeling on Clustered Taxa Counts with Repeated Measures

$140,000 – PI –W Xu

 

2016-2018                   CCSRI, Canadian Cancer Society Research Institute

Early detection of tumour response for adaptive therapy in oropharynx cancer

$200,000 – PI –S Bratman;Co-I – W Xu, F Liu, J Waldron, T Pugh

 

2016-2018                   CIHR, Canadian Institutes of Health Research

X-chromosome wide genetic association on cancer prognostic and pharmacogenetic analysis of clinical trials: methodological development and analysis

$150,000 – PI –W Xu,G Liu; Co-I – R Hung, B Chen, C O’Callaghan

 

2016-2017                   US DOD, Department of Defense

Identifying a reversible genetic factor that drives lung cancer in veteran African Americans to foster the early detection and prevention of lung cancer

$100,000 – PI –W Xu,D Reisman

 

2016-2017                   Princess Margaret Cancer Foundation Invest in Research Grant

Impact of distinct HPV subtypes on survival in oropharyngeal cancer

$100,000 – PI – S Bratman; Co-I – W Xu, F Liu, J Bruce, T Pugh

 

2014-2016                   McLaughlin Center Accelerator Grant

Early Detection of Lung Cancer Using Next Generation Sequencing Technology

$50,000 – PI –W Xu,G Liu; Co-I – R Hung, P Hu

 

2013-2014                   OICR, Ontario Institute for Cancer Research

Pharmacokinetic and Pharmacogenetic analysis of NCIC CTG CO.20 and CO.17  Clinical Trials

$128,945 – PI –W Xu,G Liu; Co-I – E Morgen, LL Siu, X Chen, CJ O’Callaghan, A Brown, D Jonker, D Tu

 

2012-2015                   CIHR, Canadian Institutes of Health Research

The Pharmacogenetics of Bevacizumab: A Companion Correlative Study of the Ovarian Cancer Clinical Trial, ICON7

$390,342 – PI – G Liu; Co-I – W Xu,R. Kim, H. MacKay, S

 

2012-2014                   CCSRI, Canadian Cancer Society Research Institute

The relationship between local breast radiation with hematopoietic stem cell trafficking, and fatigue.

$198,320 – PI –  FF Liu; Co-I – W Xu, M Li, M Minden, 

Multivariate Association of Cardiovascular Disease Risk Factors in People with Type 1 diabetes, Fellowship Clinical Research Project. Funding Sources: 2016/9 - 2018/8, CIHR STAGE, Total Funding - 90,000 CAD

Travel Award 2017,         Banting and Best Diabetes Center, 1000 CAD

Travel Award 2017,         The Hospital for Sick Children, 1000 CAD

Travel Award 2016,         Mc Laughlin Center, University of Toronto, 1000 CAD

CIHR STAGE (Strategic Training for Advanced Genetic Epidemiology) fellowship (2020-2022)

Grant Institutions

CIHR, Canadian Institutes of Health Research

Prostate Cancer Canada

Princess Margaret Cancer Centre Foundation

 

CCC, Crohn’s and Colitis Canada

OICR, Ontario Institute for Cancer Research

NSERC, Natural Sciences and Engineering Research Council of Canada ​

 

 

 

 

 

Children’s Oncology Group Adolescent and Young Adult AFLAC Grant

Banting and Best Diabetes Centre

The Hospital For Sick Children

Mc Laughlin Center, University of Toronto

UHN Princess Margaret Hospital